AIxCrypto Holdings, Inc.
AIxCrypto Holdings, Inc. (AIXC) Stock Competitors & Peer Comparison
See (AIXC) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AIXC | $1.28 | -5.19% | 6.6M | -0.15 | -$8.33 | N/A |
| ONC | $293.27 | -3.73% | 31.3B | 66.50 | $4.41 | N/A |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +2.09% |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| AVLN | $29.84 | -2.55% | 1.2B | -14.63 | -$2.04 | N/A |
| CGEM | $15.73 | -2.60% | 966.7M | -4.67 | -$3.37 | N/A |
| ATAI | $4.01 | -0.74% | 757.3M | -1.41 | -$2.84 | N/A |
| HITI | $2.41 | +0.42% | 211.8M | -5.74 | -$0.42 | N/A |
| LFMD | $4.33 | -2.70% | 209.4M | -9.84 | -$0.44 | N/A |
Stock Comparison
AIXC vs ONC Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, ONC has a market cap of 31.3B. Regarding current trading prices, AIXC is priced at $1.28, while ONC trades at $293.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas ONC's P/E ratio is 66.50. In terms of profitability, AIXC's ROE is -0.94%, compared to ONC's ROE of +0.12%. Regarding short-term risk, AIXC is more volatile compared to ONC. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check ONC's competition here
AIXC vs WBA Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, AIXC is priced at $1.28, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas WBA's P/E ratio is -1.64. In terms of profitability, AIXC's ROE is -0.94%, compared to WBA's ROE of -0.39%. Regarding short-term risk, AIXC is more volatile compared to WBA. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check WBA's competition here
AIXC vs HROWL Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, AIXC is priced at $1.28, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas HROWL's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -0.94%, compared to HROWL's ROE of -0.34%. Regarding short-term risk, AIXC is more volatile compared to HROWL. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check HROWL's competition here
AIXC vs HROWM Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, AIXC is priced at $1.28, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas HROWM's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -0.94%, compared to HROWM's ROE of -0.34%. Regarding short-term risk, AIXC is more volatile compared to HROWM. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check HROWM's competition here
AIXC vs AVLN Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, AVLN has a market cap of 1.2B. Regarding current trading prices, AIXC is priced at $1.28, while AVLN trades at $29.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas AVLN's P/E ratio is -14.63. In terms of profitability, AIXC's ROE is -0.94%, compared to AVLN's ROE of N/A. Regarding short-term risk, AIXC is less volatile compared to AVLN. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check AVLN's competition here
AIXC vs CGEM Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, CGEM has a market cap of 966.7M. Regarding current trading prices, AIXC is priced at $1.28, while CGEM trades at $15.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas CGEM's P/E ratio is -4.67. In terms of profitability, AIXC's ROE is -0.94%, compared to CGEM's ROE of -0.51%. Regarding short-term risk, AIXC is more volatile compared to CGEM. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check CGEM's competition here
AIXC vs ATAI Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, ATAI has a market cap of 757.3M. Regarding current trading prices, AIXC is priced at $1.28, while ATAI trades at $4.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas ATAI's P/E ratio is -1.41. In terms of profitability, AIXC's ROE is -0.94%, compared to ATAI's ROE of -3.66%. Regarding short-term risk, AIXC is more volatile compared to ATAI. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check ATAI's competition here
AIXC vs HITI Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, HITI has a market cap of 211.8M. Regarding current trading prices, AIXC is priced at $1.28, while HITI trades at $2.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas HITI's P/E ratio is -5.74. In terms of profitability, AIXC's ROE is -0.94%, compared to HITI's ROE of -0.41%. Regarding short-term risk, AIXC is more volatile compared to HITI. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check HITI's competition here
AIXC vs LFMD Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, LFMD has a market cap of 209.4M. Regarding current trading prices, AIXC is priced at $1.28, while LFMD trades at $4.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas LFMD's P/E ratio is -9.84. In terms of profitability, AIXC's ROE is -0.94%, compared to LFMD's ROE of -1.72%. Regarding short-term risk, AIXC is more volatile compared to LFMD. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check LFMD's competition here
AIXC vs LFMDP Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, LFMDP has a market cap of 163M. Regarding current trading prices, AIXC is priced at $1.28, while LFMDP trades at $23.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas LFMDP's P/E ratio is -10.59. In terms of profitability, AIXC's ROE is -0.94%, compared to LFMDP's ROE of -1.72%. Regarding short-term risk, AIXC is more volatile compared to LFMDP. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check LFMDP's competition here
AIXC vs LFLY Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, LFLY has a market cap of 114.9M. Regarding current trading prices, AIXC is priced at $1.28, while LFLY trades at $37.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas LFLY's P/E ratio is -0.04. In terms of profitability, AIXC's ROE is -0.94%, compared to LFLY's ROE of +0.17%. Regarding short-term risk, AIXC is less volatile compared to LFLY. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check LFLY's competition here
AIXC vs YI Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, YI has a market cap of 50.5M. Regarding current trading prices, AIXC is priced at $1.28, while YI trades at $5.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas YI's P/E ratio is -5.18. In terms of profitability, AIXC's ROE is -0.94%, compared to YI's ROE of +0.08%. Regarding short-term risk, AIXC is more volatile compared to YI. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check YI's competition here
AIXC vs PETS Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, PETS has a market cap of 47.7M. Regarding current trading prices, AIXC is priced at $1.28, while PETS trades at $2.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas PETS's P/E ratio is -0.72. In terms of profitability, AIXC's ROE is -0.94%, compared to PETS's ROE of -1.22%. Regarding short-term risk, AIXC is more volatile compared to PETS. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check PETS's competition here
AIXC vs SDEV Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, SDEV has a market cap of 44.7M. Regarding current trading prices, AIXC is priced at $1.28, while SDEV trades at $1.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas SDEV's P/E ratio is -0.29. In terms of profitability, AIXC's ROE is -0.94%, compared to SDEV's ROE of +12.37%. Regarding short-term risk, AIXC is less volatile compared to SDEV. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check SDEV's competition here
AIXC vs RAD Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, AIXC is priced at $1.28, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas RAD's P/E ratio is -0.05. In terms of profitability, AIXC's ROE is -0.94%, compared to RAD's ROE of +2.76%. Regarding short-term risk, AIXC is less volatile compared to RAD. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check RAD's competition here
AIXC vs RNTX Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, RNTX has a market cap of 29.4M. Regarding current trading prices, AIXC is priced at $1.28, while RNTX trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas RNTX's P/E ratio is -0.54. In terms of profitability, AIXC's ROE is -0.94%, compared to RNTX's ROE of -2.58%. Regarding short-term risk, AIXC is less volatile compared to RNTX. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check RNTX's competition here
AIXC vs KYNB Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, KYNB has a market cap of 27.6M. Regarding current trading prices, AIXC is priced at $1.28, while KYNB trades at $6.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas KYNB's P/E ratio is -0.49. In terms of profitability, AIXC's ROE is -0.94%, compared to KYNB's ROE of -1.82%. Regarding short-term risk, AIXC is more volatile compared to KYNB. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check KYNB's competition here
AIXC vs NEUP Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, NEUP has a market cap of 25.5M. Regarding current trading prices, AIXC is priced at $1.28, while NEUP trades at $4.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas NEUP's P/E ratio is -6.86. In terms of profitability, AIXC's ROE is -0.94%, compared to NEUP's ROE of -15.59%. Regarding short-term risk, AIXC is less volatile compared to NEUP. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check NEUP's competition here
AIXC vs MEDS Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, MEDS has a market cap of 13.3M. Regarding current trading prices, AIXC is priced at $1.28, while MEDS trades at $7.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas MEDS's P/E ratio is -0.31. In terms of profitability, AIXC's ROE is -0.94%, compared to MEDS's ROE of -2.36%. Regarding short-term risk, AIXC is less volatile compared to MEDS. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check MEDS's competition here
AIXC vs POM Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, POM has a market cap of 12.1M. Regarding current trading prices, AIXC is priced at $1.28, while POM trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas POM's P/E ratio is -1.89. In terms of profitability, AIXC's ROE is -0.94%, compared to POM's ROE of +0.07%. Regarding short-term risk, AIXC is less volatile compared to POM. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check POM's competition here
AIXC vs CJJD Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, AIXC is priced at $1.28, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas CJJD's P/E ratio is -0.46. In terms of profitability, AIXC's ROE is -0.94%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, AIXC is more volatile compared to CJJD. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check CJJD's competition here
AIXC vs MSLE Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, MSLE has a market cap of 9M. Regarding current trading prices, AIXC is priced at $1.28, while MSLE trades at $7.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas MSLE's P/E ratio is -4.27. In terms of profitability, AIXC's ROE is -0.94%, compared to MSLE's ROE of -0.52%. Regarding short-term risk, AIXC is more volatile compared to MSLE. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check MSLE's competition here
AIXC vs SSY Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, AIXC is priced at $1.28, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas SSY's P/E ratio is -2.86. In terms of profitability, AIXC's ROE is -0.94%, compared to SSY's ROE of -0.15%. Regarding short-term risk, AIXC is less volatile compared to SSY. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check SSY's competition here
AIXC vs HKPD Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, HKPD has a market cap of 5.8M. Regarding current trading prices, AIXC is priced at $1.28, while HKPD trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas HKPD's P/E ratio is -8.84. In terms of profitability, AIXC's ROE is -0.94%, compared to HKPD's ROE of -0.01%. Regarding short-term risk, AIXC is less volatile compared to HKPD. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check HKPD's competition here
AIXC vs MDVL Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, AIXC is priced at $1.28, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas MDVL's P/E ratio is -0.05. In terms of profitability, AIXC's ROE is -0.94%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, AIXC is less volatile compared to MDVL. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check MDVL's competition here
AIXC vs ATNFW Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, AIXC is priced at $1.28, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas ATNFW's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -0.94%, compared to ATNFW's ROE of -0.91%. Regarding short-term risk, AIXC is less volatile compared to ATNFW. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check ATNFW's competition here
AIXC vs BGMSP Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, AIXC is priced at $1.28, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas BGMSP's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -0.94%, compared to BGMSP's ROE of -2.95%. Regarding short-term risk, AIXC is more volatile compared to BGMSP. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check BGMSP's competition here
AIXC vs NVOH Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, NVOH has a market cap of 2.2M. Regarding current trading prices, AIXC is priced at $1.28, while NVOH trades at $24.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas NVOH's P/E ratio is 12.88. In terms of profitability, AIXC's ROE is -0.94%, compared to NVOH's ROE of +0.00%. Regarding short-term risk, AIXC is more volatile compared to NVOH. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check NVOH's competition here
AIXC vs BGMS Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, BGMS has a market cap of 2.2M. Regarding current trading prices, AIXC is priced at $1.28, while BGMS trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas BGMS's P/E ratio is -0.15. In terms of profitability, AIXC's ROE is -0.94%, compared to BGMS's ROE of -0.58%. Regarding short-term risk, AIXC is more volatile compared to BGMS. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check BGMS's competition here
AIXC vs AZNH Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, AIXC is priced at $1.28, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas AZNH's P/E ratio is 38.35. In terms of profitability, AIXC's ROE is -0.94%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, AIXC is more volatile compared to AZNH. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check AZNH's competition here
AIXC vs LFLYW Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, AIXC is priced at $1.28, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas LFLYW's P/E ratio is -0.04. In terms of profitability, AIXC's ROE is -0.94%, compared to LFLYW's ROE of +0.17%. Regarding short-term risk, AIXC is more volatile compared to LFLYW. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check LFLYW's competition here
AIXC vs BIMI Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, BIMI has a market cap of 1.2K. Regarding current trading prices, AIXC is priced at $1.28, while BIMI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas BIMI's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -0.94%, compared to BIMI's ROE of -2.94%. Regarding short-term risk, AIXC is more volatile compared to BIMI. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check BIMI's competition here
AIXC vs ESRX Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, AIXC is priced at $1.28, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas ESRX's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -0.94%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, AIXC is more volatile compared to ESRX. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check ESRX's competition here
AIXC vs SHPG Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, SHPG has a market cap of 0. Regarding current trading prices, AIXC is priced at $1.28, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas SHPG's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -0.94%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, AIXC is more volatile compared to SHPG. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check SHPG's competition here
AIXC vs POZN Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, POZN has a market cap of 0. Regarding current trading prices, AIXC is priced at $1.28, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas POZN's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -0.94%, compared to POZN's ROE of +0.61%. Regarding short-term risk, AIXC is less volatile compared to POZN. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check POZN's competition here
AIXC vs CPD Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, CPD has a market cap of 0. Regarding current trading prices, AIXC is priced at $1.28, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas CPD's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -0.94%, compared to CPD's ROE of N/A. Regarding short-term risk, AIXC is more volatile compared to CPD. This indicates potentially higher risk in terms of short-term price fluctuations for AIXC.Check CPD's competition here
AIXC vs IPXL Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, AIXC is priced at $1.28, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas IPXL's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -0.94%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, AIXC is less volatile compared to IPXL. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check IPXL's competition here
AIXC vs OREX Comparison May 2026
AIXC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AIXC stands at 6.6M. In comparison, OREX has a market cap of 0. Regarding current trading prices, AIXC is priced at $1.28, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AIXC currently has a P/E ratio of -0.15, whereas OREX's P/E ratio is N/A. In terms of profitability, AIXC's ROE is -0.94%, compared to OREX's ROE of -0.54%. Regarding short-term risk, AIXC is less volatile compared to OREX. This indicates potentially lower risk in terms of short-term price fluctuations for AIXC.Check OREX's competition here